A new peer-reviewed clinical study investigating Bonolive — Solabia Nutrition’s flagship olive leaf extract for women’s health — has been published in an international scientific journal.
The study was conducted by Solabia Nutrition’s internal R&D team in collaboration with researchers at Maastricht University.
This randomised, double-blind, placebo-controlled trial examined whether 12 weeks of Bonolive supplementation could influence circulating biomarkers of tissue ageing and remodelling in menopausal women, while also exploring Bonolive’s effects on skin quality in an exploratory subgroup.
Bonolive is a clinically validated extract from Manzanilla olive leaves, standardised for 40% oleuropein.
Oleuropein has demonstrated potent antioxidant and anti-inflammatory properties.
In previously published clinical studies in menopausal women, Bonolive has established its beneficial effects on increasing bone-formation markers, reducing joint pain and improving blood lipid profile — all key domains for Menopausal women’s quality of life.
The study
A total of 65 healthy menopausal women (45-70 years) were randomised to consume either 250 mg Bonolive or a placebo daily for 12 weeks.
Systemic markers evaluated included: elastin, collagen, hydroxyproline, pentosidine (an advanced glycation end product) and fasting glucose.
In an exploratory subgroup of 26 participants, skin structure and quality were assessed using video dermoscopy at baseline, week six and week 12.
Bonolive demonstrated notable effects on markers associated with tissue ageing, with pentosidine, a key marker of cellular ageing, decreasing in the Bonolive group compared with the placebo group.
Elastin levels remained stable with Bonolive, while they increased in the placebo group, indicating a protective effect of Bonolive on tissue integrity.
In the dermoscopy subgroup, Bonolive supplementation was associated with measurable improvements in skin microstructure, with a significant reduction in pore number between weeks six and 12 (p = 0.0012).
At week 12, the Bonolive group had significantly fewer pores compared to placebo (p = 0.034).
Surface skewness, an indicator of skin texture, improved significantly with Bonolive intake (p = 0.02).
These exploratory findings point toward a localised dermal effect of Bonolive on skin microstructure